Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 5298 Florida 4434 Illinois 2479 Georgia 2363 Arizona 2240
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Janssen Research & Development, LLC41 Eli Lilly and Company40 AbbVie35 Merck Sharp & Dohme LLC34
State
California5298 Florida4434 Illinois2479 Georgia2363 Arizona2240
All 51 states
Target enrolment
to

Trials with a site in Michigan

1487 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Recruiting
Epygenix
Phase 3
260
Arkansas, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Nebraska
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Active, closed
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Active, closed
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
California, Florida, Massachusetts, Michigan, New York, North Carolina, Ohio, Texas
2025-04-04
Recruiting
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Active, closed
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Recruiting
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Recruiting
Tissue Repair Gel in Venous Leg Ulcers in AU/US
NCT06707103Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugGlucoprime
TR Therapeutics
Phase 3
312
Florida, Michigan, New York, Texas
2025-04
Not yet open
Cranial Remolding Orthosis Registry
NCT06762691Plagiocephaly, Brachycephaly, Asymmetric Head
Otto Bock HealthCare LP
Observational
500
Michigan
2025-04
Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
Context Therapeutics Inc.
Phase 1
70
Colorado, Illinois, Michigan, New Jersey, Pennsylvania, Tennessee, Texas
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Florida, Michigan, Nevada, New Jersey, New York
2025-03-28
Active, closed
Sanofi
Phase 2
204
Arizona, Connecticut, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania
2025-03-28
Recruiting
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Recruiting
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Recruiting
ModernaTX, Inc.
Phase 1
42
California, Michigan, Texas, Utah
2025-03-25
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
DrugsLetrozole·Fulvestrant
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-03-25
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Active, closed
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Recruiting
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Sanofi
Phase 2
64
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-03-17
Active, closed
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
DrugsRapamycin·Sirolimus
Umoja Biopharma
Phase 1
106
California, Illinois, Michigan, Missouri, Nebraska, Ohio, Washington
2025-03-10
Recruiting
Takeda
Phase 3
600
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
NCT06397131Macular Telangiectasia Type 2
Neurotech Pharmaceuticals
Phase 3
12
California, Michigan, Texas
2025-03-06
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Active, closed
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Active, closed
Aerin Medical
Observational
400
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan
2025-02-28
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT06590961Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.
Phase 1
94
Michigan, Oklahoma, Texas
2025-02-20
Recruiting
Pro-2-Cool Pivotal Trial II
NCT06929923Concussion, Mild
TecTraum Inc.
Not applicable
66
Michigan, Ohio
2025-02-20
Recruiting
Eli Lilly and Company
Phase 1
127
California, Florida, Michigan, Texas, Washington
2025-02-18
Recruiting
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Active, closed
Bristol-Myers Squibb
Phase 1/2
360
California, Michigan, New Jersey, Pennsylvania
2025-02-12
Recruiting
Impax Laboratories, LLC
Phase 4
220
Arizona, Arkansas, California, Florida, Illinois, Kansas, Michigan, Nevada
2025-02-12
Recruiting
Rivermark Medical
Not applicable
215
California, Colorado, Florida, Illinois, Louisiana, Michigan, Nevada, New York
2025-02-10
Active, closed
GlaxoSmithKline
Phase 2
307
Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Michigan
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
Zura Bio Inc
Phase 2
80
California, Florida, Iowa, Massachusetts, Michigan, Texas
2025-02-06
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Cetuximab
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Active, closed
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
Novelty Nobility, Inc.
Phase 1
67
Michigan, Ohio, Oregon, Texas, Virginia
2025-02-03
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
Takeda
Phase 3
70
Arizona, California, Illinois, Michigan, New Jersey, New York, Ohio, Oklahoma
2025-01-22
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
NCT06182397Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Concept Medical Inc.
Not applicable
368
Arizona, California, Florida, Iowa, Michigan, New Jersey, New York, Ohio
2025-01-16
Recruiting
Biogen
Phase 1
78
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Pennsylvania, Texas
2025-01-16
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Recruiting
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
NCT07701161Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Neurogen Biomarking LLC
Observational
1,000
Illinois, Michigan, North Carolina
2025-01-13
Recruiting
BlossomHill Therapeutics
Phase 1/2
675
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2025-01-09
Recruiting
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Ohio, Pennsylvania, Texas
2025-01-08
Recruiting
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Recruiting
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugsKeytruda·Pembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Arizona, California, Florida, Georgia, Illinois, Michigan, Minnesota, New York
2024-12-30
Active, closed
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2024-12-23
Active, closed
ViiV Healthcare
Phase 2
229
Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Missouri
2024-12-20
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
Sanofi
Phase 2
84
Alabama, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nevada
2024-12-19
Active, closed
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
DrugsPalazestrant·Fulvestrant
Olema Pharmaceuticals, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Recruiting
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma, Tennessee
2024-12-16
Active, closed
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Active, closed
Radiopharm Theranostics, Ltd
Phase 2
30
Illinois, Indiana, Michigan
2024-12-13
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
California, Florida, Georgia, Massachusetts, Michigan, Oregon, Pennsylvania, Texas
2024-12-11
Recruiting
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 1
292
Massachusetts, Michigan
2024-12-11
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Active, closed
Sanofi
Phase 2
260
Arizona, Connecticut, Florida, Illinois, Michigan, Mississippi, Nevada, New York
2024-12-10
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Active, closed
Vicore Pharma AB
Phase 2
378
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2024-12-09
Recruiting
Kuros Biosurgery AG
Not applicable
60
California, Michigan, Missouri, Pennsylvania, Tennessee, Washington
2024-12-06
Active, closed
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Active, closed
Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations
NCT06713577Dental Prosthesis Failure, Dental Prosthesis Complication
Dentsply Sirona Implants and Consumables
Observational
82
Michigan
2024-12-03
Recruiting
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 2
48
California, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2024-11-21
Recruiting
DeepQure Inc.
Not applicable
15
California, Florida, Georgia, Michigan, Minnesota
2024-11-21
Recruiting
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
NCT06699056Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
Peerbridge Health, Inc
Observational
2,000
California, Michigan, New Jersey, New York, North Carolina, Texas
2024-11-21
Active, closed
Avalus Ultra Post-Approval Study (PAS)
NCT06506903Aortic Valve Disease
Medtronic Cardiac Surgery
Not applicable
190
Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio
2024-11-20
Active, closed
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Recruiting
Syntrix Biosystems, Inc.
Phase 2
53
California, Michigan, Minnesota, North Carolina, Wisconsin
2024-11-18
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 1
300
Connecticut, Florida, Indiana, Michigan, New York, Oklahoma, Tennessee, Texas
2024-11-18
Recruiting
E-Star BioTech, LLC
Phase 2
120
Arkansas, California, Florida, Georgia, Illinois, Michigan, Mississippi, New York
2024-11-17
Active, closed
Pfizer
Phase 3
200
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
66
Arizona, Arkansas, California, Florida, Illinois, Kentucky, Michigan, Oregon
2024-11-11
Recruiting
argenx
Phase 2
81
Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, Pennsylvania
2024-11-11
Active, closed
Abbott Medical - VERITAS Study
NCT06707688Atrial Fibrillation (AF), Stoke
Abbott Medical Devices
Not applicable
458
Arizona, Arkansas, Florida, Georgia, Kansas, Michigan, Minnesota, Nebraska
2024-11-07
Active, closed
Amgen
Phase 2
409
Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2024-11-07
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
100
Alabama, Georgia, Illinois, Iowa, Michigan, Virginia
2024-11-06
Recruiting
Takeda
Phase 3
24
Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada
2024-11-06
Recruiting
Pfizer
Phase 1
119
California, Florida, Michigan, Pennsylvania
2024-11-05
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
NCT06492733Chronic Total Occlusion of Artery of the Extremities
Versono Medical Ltd
Not applicable
65
Delaware, Florida, Iowa, Louisiana, Michigan, Tennessee
2024-11-05
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
DrugsNKX019·Fludarabine·Cyclophosphamide
Nkarta, Inc.
Phase 1/2
240
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-11-04
Recruiting
argenx
Observational
680
California, Florida, Illinois, Iowa, Kansas, Kentucky, Massachusetts, Michigan
2024-11-04
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nebraska, New York
2024-11-04
Recruiting
Coherus Oncology, Inc.
Phase 4
100
Arkansas, California, Georgia, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2024-11-01
By invitation
AgelessRx
Early Phase 1
150
Michigan
2024-11-01
Recruiting
A Study of DM005 in Patients With Advanced Solid Tumors
NCT06515990Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Phase 1/2
208
Michigan, Texas, Virginia
2024-10-31
Active, closed
Dren Bio
Phase 1
81
California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania
2024-10-30
Active, closed
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Recruiting
The THOR IDE Study
NCT05916950Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Philips Clinical & Medical Affairs Global
Not applicable
155
California, Colorado, Florida, Iowa, Louisiana, Maine, Massachusetts, Michigan
2024-10-29
Recruiting
Eli Lilly and Company
Phase 1
128
California, Florida, Georgia, Michigan, New Jersey, North Carolina
2024-10-29
Recruiting
Iovance Biotherapeutics, Inc.
Phase 2
60
Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma
2024-10-29
Recruiting
Rapid Medical
Observational
424
California, Michigan, New York
2024-10-28
Active, closed
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Active, closed
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Recruiting
Shoulder Innovations Clinical Data Registry
NCT06754150Shoulder Arthroplasty
Shoulder Innovations
Observational
2,500
Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan
2024-10-23
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-23
Recruiting
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT06511141Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
Axonics, Inc.
Not applicable
150
Alabama, Arizona, California, Florida, Louisiana, Maryland, Michigan, Minnesota
2024-10-22
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
DrugsFolfiri·Folfox·Bevacizumab
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
960
Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, North Carolina
2024-10-15
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 3
24
Alabama, Florida, Massachusetts, Michigan, Pennsylvania, Texas, Wisconsin
2024-10-14
Recruiting
HistoSonics, Inc.
Observational
5,000
California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan
2024-10-14
Active, closed
Incyte Corporation
Phase 3
349
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan
2024-10-10
Active, closed
Incyte Corporation
Phase 3
346
Arizona, California, Florida, Kentucky, Maryland, Massachusetts, Michigan, New Hampshire
2024-10-10
Active, closed
Bristol-Myers Squibb
Phase 1
213
Arizona, California, Michigan, South Dakota, Texas
2024-10-10
Active, closed
MeiraGTx Ocular UK Ltd
Phase 2
24
Massachusetts, Michigan
2024-10-10
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Arizona, California, Florida, Illinois, Louisiana, Michigan, New York, Tennessee
2024-10-09
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Active, closed
Boston Scientific Corporation
Phase 3
20
Arizona, California, Georgia, Michigan, New York, Ohio, Pennsylvania, Rhode Island
2024-10-07
Recruiting
Amgen
Phase 1
220
California, Illinois, Michigan, South Dakota, Texas, Washington
2024-10-07
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Recruiting
Abbott Nutrition
Not applicable
96
Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2024-09-27
Active, closed
Jenscare Innovation Inc.
Not applicable
15
California, Michigan, New York
2024-09-26
Recruiting
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
DrugsOlvi-Vec·Olvimulogene nanivacirepvec·Docetaxel·Cisplatin
Genelux Corporation
Phase 2
142
Arizona, Florida, Michigan, New Jersey, Ohio, Texas
2024-09-26
Recruiting
GAP Innovations, PBC
Observational
1,200
Florida, Illinois, Michigan, Nevada, New York, Ohio, Pennsylvania, Rhode Island
2024-09-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi
2024-09-26
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
Applied Biologics, LLC
Not applicable
124
Michigan
2024-09-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas
2024-09-20
Active, closed
argenx
Phase 3
141
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey
2024-09-18
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Maryland, Massachusetts, Michigan, New York, Pennsylvania, Washington
2024-09-16
Active, closed
Janssen Research & Development, LLC
Phase 2
11
Iowa, Kentucky, Michigan, New York, Pennsylvania
2024-09-16
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
The TRICURE EFS Study
NCT06506942Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
TRiCares
Not applicable
15
Georgia, Illinois, Michigan, Minnesota, New York, Ohio, South Carolina
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan
2024-09-11
Active, closed
Noema Pharma AG
Phase 2
164
Arizona, California, Florida, Georgia, Massachusetts, Michigan, Missouri, Nebraska
2024-09-10
Recruiting
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Active, closed
Amgen
Phase 3
315
California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas
2024-09-09
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas
2024-09-05
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-09-03
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Arizona, California, Florida, Georgia, Louisiana, Maryland, Massachusetts, Michigan
2024-09-03
Recruiting
Highridge Medical
Not applicable
97
California, Michigan
2024-09-01
Active, closed
Fractyl Health Inc.
Not applicable
315
Arizona, California, Florida, Indiana, Michigan, New Hampshire, New York, Pennsylvania
2024-09-01
Recruiting
NeuroTrainer Cognitive Training For Academic Focus
NCT06512974ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
NeuroTrainer
Not applicable
155
Michigan, Nebraska, Wisconsin
2024-09-01
Recruiting
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Observational
200
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2024-08-30
Active, closed
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182Clostridioides Difficile Infection
Lumen Bioscience, Inc.
Phase 2/3
375
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York
2024-08-29
Active, closed
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Recruiting
Bayer
Phase 3
555
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2024-08-28
Active, closed
Viridian Therapeutics, Inc.
Phase 3
204
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Recruiting
Prevail Therapeutics
Phase 1
124
Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas
2024-08-27
Active, closed
Viridian Therapeutics, Inc.
Phase 3
132
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Recruiting
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Recruiting
Opna Bio LLC
Phase 1
130
Arizona, California, Georgia, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-08-22
Active, closed
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Active, closed
Rgenta Therapeutics Inc
Phase 1
105
Massachusetts, Michigan, New York, Texas, Virginia, Washington
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Recruiting
Talphera, Inc
Not applicable
70
California, Florida, Michigan, New Mexico, New York, Ohio, Pennsylvania, South Carolina
2024-08-15
Recruiting
AbbVie
Phase 2
60
California, Michigan
2024-08-14
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
Hoffmann-La Roche
Phase 4
28
Arkansas, California, Colorado, Florida, Georgia, Michigan, Pennsylvania, Texas
2024-08-14
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315STEMI - ST Elevation Myocardial Infarction, AMI
TherOx
Observational
1,000
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-08-13
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
DrugPelabresib
Novartis Pharmaceuticals
Phase 3
50
California, Florida, Illinois, Michigan, New York
2024-08-13
Recruiting
Melodi Matrix™ in Breast Reconstruction
NCT06027996Breast Reconstruction
Melodi Health, Inc.
Not applicable
702
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, South Carolina, South Dakota
2024-08-09
Active, closed
Incyte Corporation
Phase 1
37
Alabama, California, Florida, Illinois, Kansas, Michigan, New York, Oregon
2024-08-08
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
102
Michigan, Ohio
2024-08-07
Active, closed
Pfizer
Observational
450
Alabama, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Minnesota
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Arizona, California, Kentucky, Michigan, New York, Pennsylvania, Texas
2024-08-07
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
705
California, Florida, Georgia, Michigan, New Jersey, New York, Ohio, Oklahoma
2024-08-05
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Washington
2024-08-05
Recruiting
BioCardia, Inc.
Not applicable
250
Florida, Georgia, Michigan, Ohio, Wisconsin
2024-08-01
Recruiting
Tempus AI
Observational
500
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2024-08-01
Recruiting
VTP-1000 in Adults With Celiac Disease
NCT06310291Celiac Disease
Barinthus Biotherapeutics
Early Phase 1
45
California, Colorado, Florida, Maryland, Michigan, Minnesota, New York, North Carolina
2024-08-01
Recruiting
Basking Biosciences, Inc.
Phase 2
228
Arizona, California, Florida, Michigan, Missouri, New Jersey, North Carolina, Ohio
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Michigan, North Carolina
2024-07-31
Active, closed
UCB Biopharma SRL
Phase 3
89
Alabama, California, Florida, Michigan, New York, Pennsylvania
2024-07-29
Recruiting
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Enterra Medical, Inc.
Not applicable
50
Florida, Kentucky, Michigan, Missouri, Oregon, Washington
2024-07-25
Active, closed
Ferrer Internacional S.A.
Phase 2
241
California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina
2024-07-23
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey
2024-07-22
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 1
240
California, Florida, Illinois, Michigan, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-22
Recruiting
Daiichi Sankyo
Phase 1/2
123
Alabama, Arizona, California, Florida, Illinois, Michigan, Minnesota, New Hampshire
2024-07-22
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
64
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Missouri
2024-07-18
Recruiting
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Recruiting
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Arizona, California, Colorado, Connecticut, Indiana, Michigan, Nevada, North Carolina
2024-07-16
Recruiting
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
NCT05399537Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Vantive Health LLC
Phase 3
40
Alabama, California, Florida, Georgia, Michigan, Ohio, Pennsylvania, South Carolina
2024-07-12
Active, closed
Areteia Therapeutics
Phase 2
30
Arkansas, California, Florida, Illinois, Indiana, Iowa, Maryland, Michigan
2024-07-09
Active, closed
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
Cabaletta Bio
Phase 2/3
37
Connecticut, Florida, Illinois, Kansas, Michigan, Minnesota, New York, North Carolina
2024-07-02
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
Intensity Therapeutics, Inc.
Phase 3
333
California, Connecticut, Michigan, Nebraska, North Carolina, Ohio, Pennsylvania
2024-06-28
Recruiting
Boehringer Ingelheim
Phase 1/2
768
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Recruiting
Panafina, Inc.
Phase 2
36
Arkansas, California, Colorado, Florida, Illinois, Indiana, Maryland, Michigan
2024-06-28
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas
2024-06-28
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, Michigan, Ohio, Tennessee
2024-06-27
Active, closed
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington
2024-06-24
Recruiting
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
NCT06445322Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Ascidian Therapeutics, Inc
Observational
50
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Texas
2024-06-20
Recruiting
H. Lundbeck A/S
Phase 2
18
Michigan, Missouri
2024-06-19
Recruiting
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
AbbVie
Phase 1
60
Arizona, Florida, Michigan, Minnesota, North Carolina, Wisconsin
2024-06-17
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis, Primary Membranous Nephropathy
DrugNKX019
Nkarta, Inc.
Phase 1/2
120
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2024-06-13
Active, closed
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Recruiting
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Arizona, California, Florida, Kansas, Maryland, Massachusetts, Michigan
2024-06-12
Recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Ascidian Therapeutics, Inc
Phase 1/2
15
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Pennsylvania
2024-06-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
California, Florida, Georgia, Michigan, Missouri, New Jersey, New York, North Dakota
2024-06-11
Recruiting
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Active, closed
Natera, Inc.
Not applicable
250
California, Colorado, Florida, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-06-10
Recruiting
X4 Pharmaceuticals
Phase 3
176
Arizona, California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri
2024-06-06
Active, closed
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Active, closed
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Active, closed
SHINKEI Therapeutics, Inc
Phase 2
45
California, Florida, Maine, Michigan, Missouri, New Jersey, New Mexico, North Carolina
2024-06-01
Active, closed
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500Advanced Solid Tumor
Quanta Therapeutics
Phase 1
240
Michigan, North Carolina, Texas, Utah
2024-05-30
Recruiting
Hoffmann-La Roche
Phase 4
28
Arkansas, Colorado, Florida, Georgia, Illinois, Michigan, New York, Pennsylvania
2024-05-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
54
Arizona, California, Connecticut, Florida, Illinois, Kansas, Michigan, Missouri
2024-05-30
Active, closed
Cytokinetics
Phase 2/3
65
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Michigan
2024-05-29
Recruiting
CDR-Life AG
Phase 1
42
Florida, Michigan, Oregon, Pennsylvania
2024-05-24
Active, closed
Study on Using Radiofrequency to Treat Moderate to Severe Acne
NCT06315166Moderate to Severe Acne Vulgaris
Pollogen
Not applicable
30
Michigan
2024-05-23
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
DrugBomedemstat
Merck Sharp & Dohme LLC
Phase 3
400
Michigan, North Carolina, Ohio, Pennsylvania
2024-05-23
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
Daiichi Sankyo
Phase 3
540
Arkansas, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2024-05-21
Active, closed
Syndax Pharmaceuticals
Phase 1
96
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2024-05-21
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri
2024-05-14
Recruiting
Encoded Therapeutics
Phase 1/2
47
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina
2024-05-14
Recruiting
Equilibra Bioscience LLC
Phase 1
31
California, Illinois, Louisiana, Michigan, Missouri, North Carolina, Pennsylvania
2024-05-10
Active, closed
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Active, closed
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, North Dakota
2024-05-03
Recruiting
Oncotelic Inc.
Phase 2/3
455
Michigan, Texas
2024-05-01
Recruiting
Octapharma
Phase 3
124
Colorado, Michigan, Ohio
2024-04-30
Active, closed
Erasca, Inc.
Phase 3
78
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2024-04-29
Recruiting
Century Therapeutics, Inc.
Observational
375
Arizona, California, Maryland, Michigan, North Carolina, Ohio, Washington
2024-04-29
Recruiting
HiberCell, Inc.
Phase 1
80
Arizona, California, Colorado, Connecticut, Michigan, Minnesota, Missouri, New York
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Recruiting
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Active, closed
ExThera Medical Corporation
Not applicable
15
District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas
2024-04-19
Recruiting
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
DrugsKB707·Docetaxel·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
250
Alabama, Arizona, California, Florida, Indiana, Louisiana, Michigan, Ohio
2024-04-17
Active, closed
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT06014762Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL)
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
120
California, Florida, Indiana, Louisiana, Michigan, New York, North Carolina, Ohio
2024-04-16
Active, closed
Edgewise Therapeutics, Inc.
Phase 2
79
California, Georgia, Massachusetts, Michigan, Missouri, New Jersey, New York, North Carolina
2024-04-11
Recruiting
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
DrugLenvatinib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Active, closed
Amgen
Phase 3
434
Arizona, California, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2024-04-08
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Active, closed
A Study of Sovilnesib in Subjects With Ovarian Cancer
NCT06084416High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Volastra Therapeutics, Inc.
Phase 1
120
Alabama, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan, New York
2024-04-04
Active, closed
Amgen
Phase 4
32
Michigan, Texas
2024-04-02
Active, closed
EpicentRx, Inc.
Phase 2
216
Arizona, Florida, Illinois, Indiana, Louisiana, Maryland, Michigan, Nevada
2024-04-02
Recruiting
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
Splice Bio
Observational
75
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan, New York
2024-03-29
Active, closed
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844Nonterminal Premolar Needing Extraction
McGuire Institute
Not applicable
70
Colorado, Massachusetts, Michigan, Nebraska, Tennessee, Texas, Wisconsin
2024-03-28
Active, closed
Gilead Sciences
Phase 3
577
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2024-03-25
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Missouri, New Hampshire
2024-03-25
Active, closed
Cook MyoSite
Phase 3
200
California, Florida, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Michigan
2024-03-21
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Active, closed
AbbVie
Phase 1
152
California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas
2024-03-08
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Active, closed
Fusion Pharmaceuticals Inc.
Phase 2
110
California, Florida, Iowa, Maryland, Michigan, Missouri, Nebraska, New Mexico
2024-03-05
Active, closed
Cynata Therapeutics Limited
Phase 2
60
Arizona, Arkansas, Florida, Georgia, Illinois, Michigan, Nebraska, New York
2024-03-04
Recruiting
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
NCT06387485Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
Ricoh USA, Inc.
Not applicable
150
California, Michigan, Ohio
2024-03-01
Recruiting
Takeda
Phase 3
50
Arizona, California, Colorado, Florida, Indiana, Iowa, Massachusetts, Michigan
2024-03-01
Active, closed
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06109181Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Lexeo Therapeutics
Phase 1/2
10
California, Maryland, Michigan, New York, South Carolina
2024-02-29
Active, closed
Cardiff Oncology
Phase 2
110
Arizona, Arkansas, California, Florida, Hawaii, Indiana, Kansas, Michigan
2024-02-27
Active, closed
CLIP-IT Post-Market Study
NCT06203054Left Atrial Appendage Exclusion
Medtronic Cardiac Surgery
Not applicable
198
Georgia, Illinois, Indiana, Michigan, Minnesota, Missouri, New York, Ohio
2024-02-26
Recruiting
Pulmonx Corporation
Not applicable
200
Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan
2024-02-22
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
Parkinson's Disease Progression Study
NCT06219629Parkinson Disease
Koneksa Health
Observational
82
Colorado, Florida, Georgia, Kansas, Massachusetts, Michigan, Nevada
2024-02-20
Active, closed
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nevada, New Jersey
2024-02-19
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
403
California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas
2024-02-12
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugBL-M07D1
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Active, closed
Lantheus Medical Imaging
Phase 4
274
Alabama, California, Georgia, Iowa, Maryland, Massachusetts, Michigan, Missouri
2024-02-08
Active, closed
Autus Valve Pivotal Study
NCT05006404Congenital Heart Disease
Edwards Lifesciences
Not applicable
62
California, Colorado, Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina
2024-02-05
Recruiting
Infinite Biomedical Technologies
Not applicable
16
Michigan
2024-02-02
Active, closed
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Recruiting
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
180
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Nevada
2024-01-31
Recruiting
CSL Behring
Phase 3
35
California, Michigan, Pennsylvania, Texas
2024-01-30
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Recruiting
Lexeo Therapeutics
Observational
40
California, Maryland, Michigan, New York
2024-01-23
Active, closed
Pfizer
Phase 3
394
California, Florida, Indiana, Louisiana, Maryland, Michigan, New Mexico, New York
2024-01-19
Active, closed
Bolt Medical
Not applicable
936
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota, Mississippi
2024-01-19
Active, closed
Arcus Biosciences, Inc.
Phase 1
91
Colorado, District of Columbia, Georgia, Michigan, New York, Pennsylvania, Texas, Utah
2024-01-19
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Montana
2024-01-18
Active, closed
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Recruiting
NorthSea Therapeutics B.V.
Phase 2
36
Arizona, California, District of Columbia, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2024-01-15
Active, closed
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Recruiting
Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns
NCT06173167Dental Disorders Hard Tissues of Teeth, Dental Diseases
Ivoclar Vivadent AG
Not applicable
70
Michigan
2024-01-08
Recruiting
Fate Therapeutics
Phase 1
351
Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York
2024-01-05
Recruiting
Tympanoseal Clinical Study
NCT05849844Tympanic Membrane Perforation
Grace Medical, Inc.
Not applicable
45
Michigan, Tennessee
2024-01-05
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
DrugsGedatolisib·Darolutamide
Celcuity Inc
Phase 1/2
54
Michigan
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Arizona, California, Colorado, Massachusetts, Michigan, Nevada, New York, North Carolina
2023-12-31
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 1
216
Florida, Michigan, Ohio, Texas
2023-12-28
Recruiting
Invenio Imaging Inc.
Observational
900
California, Florida, Michigan, New York, North Carolina, Texas
2023-12-21
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Arizona, California, Florida, Illinois, Massachusetts, Michigan, North Carolina, Texas
2023-12-20
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
DrugREM-422
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2023-12-20
Recruiting
Danon Disease Natural History Study
NCT06214507Danon Disease
Rocket Pharmaceuticals Inc.
Observational
60
Arizona, California, Colorado, Florida, Michigan, Missouri, New York, Texas
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Active, closed
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
DrugFenretinide
SciTech Development, Inc.
Phase 1
46
Arizona, California, Colorado, Illinois, Michigan, New York, Pennsylvania, Texas
2023-12-18
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Arizona, California, Florida, Indiana, Kentucky, Maryland, Massachusetts, Michigan
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Recruiting
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
Aura Biosciences
Phase 3
108
California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2023-12-06
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Active, closed
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
BioNTech SE
Phase 1
41
Michigan, North Carolina, Ohio
2023-11-30
Active, closed
Incyte Corporation
Phase 3
467
Alabama, California, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2023-11-29
Active, closed
Bayer
Observational
300
Maryland, Michigan, New York, Ohio, Pennsylvania
2023-11-27
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Arizona, California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio
2023-11-27
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2023-11-20
Active, closed
Renibus Therapeutics, Inc.
Observational
200
Alabama, Indiana, Michigan, Texas
2023-11-18
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Michigan
2023-11-17
Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
NCT05874921Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
DrugMitomycin C
UroGen Pharma Ltd.
Observational
450
California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan
2023-11-17
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
Nektar Therapeutics
Phase 2
396
Arkansas, California, Florida, Georgia, Indiana, Kentucky, Michigan, Nevada
2023-11-15
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2023-11-14
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2/3
1,074
Arizona, California, Florida, Illinois, Louisiana, Maryland, Michigan, Missouri
2023-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
Xentria, Inc.
Phase 1/2
32
Alabama, Colorado, Florida, Illinois, Iowa, Maryland, Michigan, Minnesota
2023-11-10
Recruiting
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Personalis Inc.
Observational
422
Arizona, Colorado, District of Columbia, Florida, Illinois, Louisiana, Michigan, Nebraska
2023-11-09
Recruiting
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Recruiting
MBrace Therapeutics
Phase 1/2
130
California, Colorado, Georgia, Illinois, Indiana, Michigan, Nevada, New Jersey
2023-11-07
Recruiting
Exegi Pharma, LLC
Phase 1/2
50
California, Florida, Michigan, Minnesota, Missouri, New York, North Carolina, Pennsylvania
2023-11-06
Recruiting
A2A Pharmaceuticals Inc.
Phase 1
86
Michigan, Oklahoma, South Carolina, Texas, Virginia
2023-11-02
Recruiting
Qualigen Theraputics, Inc.
Phase 1
54
Arizona, Connecticut, Michigan, Texas
2023-11-01
Recruiting
LeonaBio
Phase 3
600
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2023-10-31
Active, closed
IDEAYA Biosciences
Phase 2/3
420
Arizona, California, Colorado, Florida, Georgia, Iowa, Massachusetts, Michigan
2023-10-31
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
DrugsKB707·Opdualag·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
240
California, Florida, Indiana, Michigan, Nebraska, New Jersey, New York, Ohio
2023-10-31
Active, closed
Cortex
Not applicable
400
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, New York
2023-10-23
Recruiting
Hoffmann-La Roche
Phase 3
182
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Michigan, Missouri
2023-10-22
Active, closed
Genentech, Inc.
Phase 2
260
California, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Nebraska
2023-10-18
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsAdagrasib·Cabozantinib
Kura Oncology, Inc.
Phase 1
300
Arizona, California, Colorado, Florida, Iowa, Massachusetts, Michigan, Minnesota
2023-10-18
Active, closed
Hummingbird Diagnostics
Observational
2,000
Georgia, Louisiana, Massachusetts, Michigan, New York, Pennsylvania, Texas, Utah
2023-10-18
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
Volastra Therapeutics, Inc.
Phase 1/2
200
California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York
2023-10-18
Recruiting
W.L.Gore & Associates
Not applicable
244
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Massachusetts, Michigan
2023-10-17
Active, closed
Celgene
Phase 3
79
California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan, Minnesota
2023-10-16
Active, closed
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
DrugsZimberelimab·Fluorouracil·Leucovorin·Oxaliplatin
Arcus Biosciences, Inc.
Phase 1
40
Arizona, Florida, Illinois, Michigan, Minnesota, New Jersey, Ohio, Texas
2023-10-13
Active, closed
Clinuvel, Inc.
Phase 3
200
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan
2023-10-11
Active, closed
Clinical Evaluation of Implants Restored With Advanced Lithium Disilicate Screw-retained Crowns
NCT05752539Dental Prosthesis Failure, Dental Prosthesis Complication
Dentsply Sirona Implants and Consumables
Observational
25
Michigan
2023-10-10
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
300
California, Massachusetts, Michigan, Tennessee, Texas
2023-10-05
Active, closed
Bristol-Myers Squibb
Phase 3
106
California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey
2023-10-05
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
California, Colorado, Florida, Kentucky, Michigan, New Jersey, Texas
2023-10-04
By invitation
Biogen
Phase 3
306
Alabama, Arizona, California, Michigan, Missouri, North Carolina, Ohio, Pennsylvania
2023-10-03
Active, closed
Brain Neurotherapy Bio, Inc.
Phase 1
9
California, Florida, Massachusetts, Michigan, New York, Ohio, Tennessee
2023-10-03
Recruiting
Pfizer
Phase 4
80
California, Colorado, Florida, Michigan, Texas
2023-10-03
Recruiting
Dendreon
Phase 2
400
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Michigan
2023-10-02
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
94
California, Florida, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon
2023-09-28
Recruiting
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT05636618Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
Perspective Therapeutics
Phase 1/2
300
Florida, Illinois, Iowa, Kentucky, Maryland, Michigan, Minnesota, Missouri
2023-09-27
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
92
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Michigan
2023-09-22
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Active, closed
Real World Registry for Use of the Ion Endoluminal System
NCT06004440Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms
Intuitive Surgical
Observational
1,301
Florida, Illinois, Kansas, Louisiana, Michigan, Minnesota, New York, North Carolina
2023-09-21
Active, closed
PharmaMar
Phase 3
469
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota
2023-09-21
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Michigan
2023-09-13
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2023-09-13
Active, closed
Cantex Pharmaceuticals
Phase 2
30
Colorado, Florida, Michigan, Missouri, New York, Oklahoma, Utah, Washington
2023-09-12
Active, closed
Adagio Medical
Not applicable
206
Arizona, California, Maryland, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2023-09-11
Recruiting
Biotest
Phase 3
590
Alabama, Arizona, California, Georgia, Maryland, Massachusetts, Michigan, Missouri
2023-09-09
Active, closed
Venclose digiRF System Post Market Study
NCT05504070Venous Reflux, Chronic Venous Insufficiency
C. R. Bard
Not applicable
203
Colorado, Hawaii, Michigan, New Jersey, North Carolina, Texas, Virginia
2023-09-08
Recruiting
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041Cataract, Presbyopia, Posterior Capsule Opacification
Bausch & Lomb Incorporated
Observational
435
Alabama, California, Florida, Illinois, Indiana, Kansas, Michigan, Nebraska
2023-09-08
Recruiting
Hoffmann-La Roche
Phase 3
230
Arizona, California, District of Columbia, Maryland, Massachusetts, Michigan, Nevada, New Jersey
2023-09-08
Recruiting
Ipsen
Phase 3
276
Arizona, Arkansas, California, Colorado, Florida, Kansas, Louisiana, Michigan
2023-08-31
Recruiting
Elute, Inc.
Not applicable
204
California, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Michigan, New York
2023-08-31
Recruiting
Pliant Therapeutics, Inc.
Phase 1
124
Connecticut, Georgia, Michigan, Missouri, New Jersey, New York, North Carolina, South Dakota
2023-08-30
By invitation
CSL Behring
Observational
56
Arizona, Arkansas, California, Colorado, Florida, Michigan, North Carolina, Oregon
2023-08-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2023-08-28
Recruiting
AstraZeneca
Phase 3
231
Alabama, Arizona, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan
2023-08-24
Recruiting
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF
Procyrion
Not applicable
320
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Mississippi
2023-08-23
Recruiting
Atsena Therapeutics Inc.
Phase 3
97
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, New York, North Carolina
2023-08-22
Recruiting
Pfizer
Phase 2
340
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2023-08-22
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Recruiting
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
Glaukos Corporation
Phase 2
84
Alabama, California, Colorado, Florida, Georgia, Indiana, Michigan, Missouri
2023-08-17
Recruiting
DualityBio Inc.
Phase 1/2
862
Arizona, California, Florida, Georgia, Kentucky, Michigan, Minnesota, Nevada
2023-08-17
Active, closed
Erasca, Inc.
Phase 1
86
California, Connecticut, Florida, Georgia, Michigan, Missouri, Nevada, Oregon
2023-08-17
Active, closed
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
NCT05712161Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification
Anteris Technologies Ltd.
Not applicable
15
Arizona, Michigan, New York, Ohio
2023-08-07
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
DrugsDFMO·Eflornithine·Temodar·Temozolomide
Orbus Therapeutics, Inc.
Phase 1
66
Alabama, Michigan, New York, North Carolina, Ohio, Rhode Island, Texas, Utah
2023-07-24
Active, closed
Hoffmann-La Roche
Phase 2
21
Alabama, Connecticut, Florida, Massachusetts, Michigan
2023-07-24
Recruiting
BioAtla, Inc.
Phase 1
168
California, Connecticut, Illinois, Michigan, Ohio, Washington
2023-07-14
Active, closed
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT05945823Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer
DrugsFutibatinib·Leucovorin·Irinotecan·Adrucil
Taiho Oncology, Inc.
Phase 2
53
California, Colorado, Florida, Michigan, New Jersey, New York, Ohio, Pennsylvania
2023-07-13
Recruiting
Harvard Apparatus Regenerative Technology, Inc.
Phase 1
10
California, Michigan, Minnesota
2023-07-13
Active, closed
Amulet™ ADVANCE LAA
NCT05997446Atrial Fibrillation, Stroke, Bleeding
Abbott Medical Devices
Observational
610
Arizona, Arkansas, Florida, Illinois, Kansas, Michigan, Nebraska, New York
2023-07-12
Active, closed
Incyte Corporation
Phase 2
247
Alabama, California, Florida, Georgia, Illinois, Michigan, New York, North Carolina
2023-07-11
Recruiting
SURGE Therapeutics
Phase 1/2
75
Arizona, Arkansas, California, Florida, Maryland, Massachusetts, Michigan, Ohio
2023-07-11
Recruiting
Recursion Pharmaceuticals Inc.
Phase 1/2
67
Arizona, California, Florida, Indiana, Louisiana, Michigan, Minnesota, Missouri
2023-07-10
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Michigan, New York, Tennessee, Texas
2023-07-10
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
California, Michigan, New York, Ohio, Texas, Utah
2023-07-06
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
California, Florida, Michigan, Ohio, Texas
2023-07-05
Active, closed
IDEAYA Biosciences
Phase 2
160
Arizona, California, Florida, Michigan, Minnesota, New York, Pennsylvania, Tennessee
2023-07-03
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Aqtual, Inc.
Observational
1,410
Arizona, California, Florida, Idaho, Illinois, Indiana, Michigan, Minnesota
2023-06-29
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Active, closed
AstraZeneca
Phase 3
111
California, Louisiana, Michigan
2023-06-27
Active, closed
USWM CT, LLC
Phase 2
66
Arizona, California, Georgia, Michigan, New Jersey, Ohio, Oklahoma, South Dakota
2023-06-26
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
California, Michigan, Nevada, Ohio
2023-06-26
Active, closed
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
TScan Therapeutics, Inc.
Observational
1,150
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2023-06-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2023-06-22
Recruiting
ModernaTX, Inc.
Observational
60
California, Maryland, Michigan, Pennsylvania, Texas, Washington
2023-06-16
Recruiting
GlaxoSmithKline
Phase 1/2
123
Arizona, California, Florida, Massachusetts, Michigan, North Carolina, Ohio, Tennessee
2023-06-14
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Arizona, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Missouri
2023-06-13
Active, closed
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
DrugsKeytruda·Pembrolizumab
Tango Therapeutics, Inc.
Phase 1/2
126
California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-06-12
Recruiting
H. Lundbeck A/S
Phase 3
315
Connecticut, Florida, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan
2023-06-07
Active, closed
Sapience Therapeutics
Phase 1
130
Alabama, California, Colorado, Louisiana, Massachusetts, Michigan, New York, North Carolina
2023-06-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Active, closed
Pelvic Fixation and Fusion During Multilevel Spinal Surgery
NCT05640908Spinal Fusion, Deformity of Spine
SI-BONE, Inc.
Observational
200
Alabama, Colorado, Michigan, Minnesota, New York, North Carolina, Texas
2023-06-05
Active, closed
Synergy Spine Solutions
Not applicable
200
Arizona, California, Colorado, Florida, Indiana, Kansas, Louisiana, Michigan
2023-06-01
Active, closed
MapLight Therapeutics
Phase 2
120
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri
2023-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
California, Colorado, District of Columbia, Florida, Georgia, Massachusetts, Michigan, Missouri
2023-05-31
Active, closed
Apellis Pharmaceuticals, Inc.
Phase 3
100
California, Colorado, Florida, Georgia, Iowa, Michigan, New Jersey, New York
2023-05-29
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
225
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New York, Tennessee
2023-05-26
Active, closed
Translational Sciences, Inc.
Phase 2
64
Arizona, California, Georgia, Maryland, Massachusetts, Michigan, North Carolina, Ohio
2023-05-24
Recruiting
Jazz Pharmaceuticals
Phase 1/2
60
California, District of Columbia, Florida, Georgia, Maryland, Michigan, New York, Ohio
2023-05-23
Active, closed
Lantheus Medical Imaging
Observational
500
Alabama, Arkansas, California, Michigan, Missouri, Nebraska, Pennsylvania, Tennessee
2023-05-22
Active, closed
MeiraGTx, LLC
Phase 1/2
13
Connecticut, Michigan, New York, Pennsylvania, West Virginia
2023-05-19
Active, closed
Francis Medical Inc.
Not applicable
400
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Minnesota
2023-05-16
Active, closed
Boehringer Ingelheim
Phase 1
59
California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia
2023-05-11
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
360
Arkansas, California, Florida, Idaho, Illinois, Maryland, Michigan, New Jersey
2023-05-09
Active, closed
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease
Intuitive Surgical
Not applicable
204
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2023-05-08
By invitation
Guided Therapeutics
Not applicable
400
Alabama, Georgia, Michigan, Virginia
2023-05-05
Active, closed
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
DrugsSC291·Fludarabine·Cyclophosphamide
Sana Biotechnology
Phase 1
16
California, Georgia, Kansas, Michigan, Nebraska, Texas
2023-05-02
Recruiting
The Ailliance Post-Market Clinical Study
NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma
Medtronic Spinal and Biologics
Not applicable
1,000
Arizona, Arkansas, California, Indiana, Kentucky, Maryland, Michigan, Minnesota
2023-05-01
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
California, Michigan, New York, Ohio, Texas, Washington
2023-04-27
Active, closed
Nalu Medical, Inc.
Not applicable
185
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, New Jersey
2023-04-27
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
DrugsJNJ-101556143·Lutetium Lu-177 vipivotide tetraxetan·Pasritamig·Cabazitaxel
Janssen Research & Development, LLC
Phase 1
300
Florida, Michigan, Missouri, New York, Pennsylvania
2023-04-26
Active, closed
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Janux Therapeutics
Phase 1
130
California, Georgia, Illinois, Michigan, Missouri, New York, North Carolina, Ohio
2023-04-19
Active, closed
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Active, closed
Lumos Labs, Inc.
Not applicable
194
Florida, Michigan, Missouri, New Jersey
2023-04-15
Active, closed
Galderma R&D
Not applicable
186
California, Connecticut, Florida, Georgia, Louisiana, Massachusetts, Michigan, New York
2023-04-12
Recruiting
Takeda
Phase 2/3
500
Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, North Carolina
2023-04-05
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Active, closed
Bayer
Phase 3
985
Arizona, California, Colorado, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2023-04-03
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Sairopa B.V.
Phase 1
130
Michigan, Missouri, Ohio, Virginia
2023-04-03
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
DrugsAbemaciclib·Fulvestrant
Incyclix Bio
Phase 1/2
150
Florida, Georgia, Indiana, Massachusetts, Michigan, New York, North Carolina, Ohio
2023-03-28
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
DrugsGV20-0251·Keytruda·Pembrolizumab
GV20 Therapeutics
Phase 1/2
365
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York
2023-03-23
Recruiting
Tvardi Therapeutics, Incorporated
Phase 1/2
193
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Michigan, Missouri
2023-03-23
Active, closed
Verastem, Inc.
Phase 1/2
40
California, Illinois, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Utah
2023-03-22
Active, closed
Imvax
Phase 2
99
Florida, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio
2023-03-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky, Michigan
2023-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
798
Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio
2023-03-13
Rows per page Showing 501–1000 of 1487
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,487 of those studies with a site in Michigan.

How many clinical trials are recruiting in Michigan?

837 of the 1,487 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 22 have not yet opened recruitment, 599 are active but closed to new participants, and 29 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.